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Inhibition of SK channel function is being pursued in animal models as a possible 
therapeutic approach to treat atrial fibrillation (AF).  However, the pharmacology of SK 
channels in human atria is unclear.  SK channel function is inhibited by both apamin 
and UCL1684, with the former discriminating between SK channel subtypes.  In this 
proof-of-principle study, the effects of apamin and UCL1684 on right atrial myocytes 
freshly isolated from patients in sinus rhythm undergoing elective cardiac surgery 
were investigated.  Outward current evoked from voltage clamped human atrial 
myocytes was reduced by these two inhibitors of SK channel function.  In contrast, 
membrane current underlying the atrial action potential was affected significantly only 
by UCL1684 and not by apamin. This pharmacology mirrors that observed in mouse 
atria, suggesting that mammalian atria possess two populations of SK channels, with 
only one population contributing to the action potential waveform.  Immuno-
visualization of the subcellular localization of SK2 and SK3 subunits showed a high 
degree of colocalization, consistent with the formation of heteromeric SK2/SK3 
channels.  These data reveal that human atrial myocytes express two SK channel 
subtypes, one exhibiting an unusual pharmacology.  These channels contribute to the 
atrial action potential waveform and might be a target for novel therapeutic 
approaches to treat supraventricular arrhythmic conditions such as atrial fibrillation. 
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Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia [1] and a major 
health issue that affects approximately 2% of the population of Europe and the USA [2, 3].  
Aging is a major risk factors for AF, and it is estimated that the prevalence of AF will double 
in the next 50 years [4].  Among the numerous consequences of AF are stroke, systemic 
embolization and heart failure [4].  The mechanistic cause of stand-alone AF is still unknown, 
although there are additional predisposing conditions such as the presence of mitral valve 
regurgitation [5] or the undertaking of cardiac surgery [6-8].  This uncertainty and variability 
has led to treatments that have a wide range of pharmacological actions [9], which are 
associated with a wide spectrum of cardiac side effects that include impaired left ventricular 
contractile function or serious arrhythmias such as atrioventricular block and QT 
prolongation (torsades de pointes) [9].  
 
Atrial action potential duration is prolonged by inhibition of SK channel function [15, 16, 20].  
Three subtypes of SK channel subunit have been cloned, termed SK1-3 [10], with both 
homomeric and heteromeric channels being able to assemble [10, 11].  There is a greater 
level of expression of SK channel subunits in human atria compared with ventricles, with 
higher levels of mRNA encoding for SK2 and 3 than for SK1 in atria [12].  The gene 
encoding SK3 was identified in a meta-analysis to be a common genetic variant present in 
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AF [13].  The association between clinical AF and SK channel expression was confirmed in 
studies of larger populations [14].  Induced AF in rats [15], horse [16] and pig [17] is 
terminated by SK channel inhibition, while co-inhibition of sodium current and SK channel 
function terminated AF in guinea pig [16].  However, the pharmacology of SK inhibition in 
atria is not straightforward.  SK channel currents are characterised by high sensitivity to the 
toxin apamin, which is found in the venom of the Honey Bee [10], which can discriminate 
between SK channel subtypes [18].  Small molecule inhibitors of SK channel function are 
available but inhibit all SK channel subtypes with equal potency [18].  However, the ability of 
inhibition of SK channel function to terminate induced AF is not generally observed with 
apamin [19].  This has led to investigators using small molecule inhibitors that provide a 
clear effect, including UCL1684, NS8593 and ICAGEN [12, 16].  For example, inhibition of 
SK channel current by NS8593 or ICAGEN prolonged the human atrial action potential 
duration (APD) [12].  Study of SK channel function in mouse atria revealed that inhibition of 
SK channel function by UCL1684 prolonged the APD, but this effect was not reproduced by 
apamin [20].  In contrast, whole-cell voltage clamp-evoked outward currents were reduced 
by both apamin and UCL1684 [20].  It was proposed that mouse atria possess two 
populations of SK channels: apamin-sensitive homomeric SK2 channels and apamin-
insensitive heteromeric SK2-SK3 channels.  Each population is activated differently, with 
both populations of channel being activated during whole-cell voltage-clamp recordings, but 
only the apamin-insensitive channels contribute to repolarization of the atrial action [20].  It is 
important to resolve which SK channel subtypes are present in human atria, as it has been 
proposed that the SK channel contributing to action potential repolarization is a therapeutic 
atrial-selective target for antiarrhythmic drug therapy [12].  We report that whole-cell voltage 
clamp current recorded from acutely isolated human atrial myocytes were reduced in 
amplitude by both apamin and UCL1684.  In contrast, membrane current underlying the 
atrial action potential was only significantly affected by UCL1684 and not apamin.  These 
data are in accord with those reported for mouse atria [20] and indicate that both human and 
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mouse possess two populations of SK channel, with only one being a therapeutic target to 
affect action potential configuration. 
 
Materials and Methods 
Patient selection and human atrial sample harvesting 
Human atrial samples were collected from 18 patients undergoing cardiac surgery at the 
Bristol Heart Institute, University Hospital NHS Foundation Trust (IRAS number 211164) 
during 2017-18 and recruited to the SKArF study.  The study received approval from the 
West of Scotland Research Ethics Committee 5 (Reference 16/WS/0172).  Informed consent 
was received from all participants.  Under general anaesthesia, following chest opening and 
heparinisation, and before commencing cardiopulmonary bypass, the tip of the right atrial 
appendage was removed as surplus tissue and plunged into pre-oxygenated sterile ice-cold 
cardioplegic solution of composition: (mM): glucose, 140; HEPES free acid, 10, adenosine, 
5, mannitol, 10, KH2PO4, 50, and MgSO4, 8mM; pH 7.4 (KOH) (284 mOsm).  Tissue was 
transferred into calcium-free (Ca2+-free) isolation solution of composition (mM): NaCl, 130; 
KCl, 5.4; Glucose, 10; HEPES free acid, 10; NaH2PO4, 0.4; MgCl2, 1.4; taurine, 20; creatine, 
10; pH 7.6 (NaOH) (285 mOsm) for cleaning and cutting into chunks.  The chunks were then 
transferred to fresh oxygenated warm Ca2+-free isolation solution and incubated for 3 
minutes at 37oC while shaking at 100 rpm.  The solution was then decanted gently through a 
nylon filter sheath (200 µm) and replaced with new oxygenated warm Ca2+-free isolation 
solution for 3 minutes.  Chunks were then placed in warm EGTA (8 µM)-containing Ca2+-free 
isolation solution and incubated for a further 3 minutes.  Tissue was transferred back into 
Ca2+-free isolation solution supplemented with bovine serum albumin (BSA) (1% w/v), 
collagenase (0.2 mg/ml) and proteinase (0.4 mg/ml) and incubated for 10 minutes at 37oC in 
a shaking water bath, with CaCl2 (20 µM) added after 10 minutes and chunks were 
incubated for a further 35 minutes at 37oC.  Tissue was then washed with fresh warm 
oxygenated Ca2+-free isolation solution and then placed in Ca2+-free isolation solution 
supplemented with CaCl2 (20 µM), BSA (1%) and collagenase (0.2 mg/ml) at 37
oC to be 
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sampled at 5 minutes intervals until the appearance of striated rod-shaped cardiomyocytes.  
Enzyme activity was then stopped by addition of foetal bovine serum (1%) and cells 
transferred into 35 mm petri-dishes containing KB storage solution of composition (mM): L-
glutamic acid, 90; KCl, 30; Glucose, 20; HEPES free acid, 10; EGTA, 1; sodium pyruvate, 5; 
NaH2PO4, 0.4; MgCl2, 5; taurine, 20; creatine, 5; succinic acid, 5; sodium butyric acid, 5; 
Na2ATP, 2; pH 7.4 (KOH) (280 mOsm). 
 
Electrophysiology 
Isolated atrial myocytes were continuously perfused with an external solution containing 
(mM): NaCl, 144; Glucose, 10; HEPES free acid, 10, KCl, 2.5; MgCl2, 1.2, CaCl2, 2.5, pH 7.4 
(NaOH) (300 mOsm).  Evoked currents were recorded using the whole-cell technique with 
electrodes pulled from KG-33 glass and containing (mM): potassium aspartate, 130; 
HEPESNa, 5; NaOH, 3; KCl, 20; CaCl2, 50 nM; MgCl2, 1.5; Na2ATP, 2.5; pH 7.4 (NaOH) 
(311 mOsm).  Cells were voltage clamped at -80 mV at room temperature, using an 
Axopatch 200A patch-clamp amplifier (Molecular Devices (UK) Ltd, Berkshire, UK).  
Currents were filtered with an 8-pole Bessel filter (Frequency Devices, IL, USA) at a cut-off 
frequency of 1 kHz and sampled at 10 kHz using Pulse software (HEKA, Lambrecht/Pfalz, 
Germany).  Electrode resistances were 4-7 MΩ and whole-cell capacitance and series 
resistance were compensated for by 20%–50%. 
 
Apamin (Sigma Aldrich, UK) and charybdotoxin (Tocris Biosciences, Bristol, UK) were 
dissolved in water and stored at a concentration of 100 μM at -20 oC, whereas UCL1684 
(Tocris Biosciences, Bristol, UK) was dissolved in DMSO and stored at a concentration of 





All electrophysiology data was analysed using Pulse (HEKA) and Origin (version 9, Originlab 
Corp, MA, USA) and Prism (version 7, Graphpad Software Inc, CA, USA).  Statistical 




Freshly isolated atrial myocytes were fixed and permeabilized by incubating with ice-cold 
acetone 100% for 7 minutes [6], followed by blocking the cells with horse serum (2.5%) 
(Vector Laboratories: DK-8828) for 30 minutes.  Cells were then incubated overnight at room 
temperature with mouse anti-SK2 antibody (Biorbyt: orb333955) and rabbit anti-SK3 
antibody (Biorbyt: orb157735), added as a 1:200 dilution in blocking solution of composition 
(mM): phosphate buffer saline, bovine serum albumin (Sigma Aldrich, A9418) (1%), and 
foetal calf serum (Thermo Fisher Scientific, 10500‐064) (2%) [20, 21].  Cells were then 
washed twice with phosphate buffered saline (PBS) and incubated for 3 hours with 
secondary antibodies in a premixed double labelling solution of anti-rabbit IgG (red DyLight 
594) and anti-mouse IgG (green DyLight 488) (Vector Laboratories: DK-8828).  Finally, cells 
were washed three times with PBS before being mounted with mounting medium with DAPI 
(Vector Laboratories: H-1200).  The cells were examined using a Leica AOBSSP2 confocal 
laser scanning microscope (Leica, Solms, Germany).  The objective used was a 40x (NA 
1.4) oil immersion lens.  Brightness and contrast were increased uniformly for each 
experiment using Volocity software (PerkinElmer, Waltham, MA).  Co-localisation of SK2 and 
SK3 subunits is quantified using Mander’s coefficient, where the emission intensities from 
each secondary antibody fluorophore are ratioed with the intensity distribution of co-






Patient baseline characteristics and risk profile are shown in Table 1.  Tissue was obtained 
from 18 patients (14 male, 4 female; mean age 67). 
Activation of SK channel current in adult human atrial myocytes 
Visualised striated, rod shaped human atrial myocytes were whole-cell voltage clamped and 
current was evoked by step depolarizations from a holding potential of -80 mV.  Evoked 
outward current increased in amplitude with depolarization, displaying typical outward 
rectification (Figure 1A).  Extracellular application of either apamin (100 nM) or UCL 1684 
(100 nM) reduced the amplitude of evoked current at all membrane potentials (Figure 1B).  
Apamin inhibited the current by 14.3 ± 2.7% at +10 mV (4 patients, n=8 cells), with current 
reduced from 500 ± 100 pA to 430 ± 100 pA (P=0.000008).  A similar reduction in 
outward current was observed with the small organic molecule inhibitor of SK current 
UCL1684, producing a reducing current amplitude at +10 mV by 17.5 ± 2.8% (4 patients, 
n=10 cells), from 500 ± 90 pA to 420 ±90 pA (P=0.00000014) (Figure 1B).  The effect of 
apamin and UCL1684 were comparable (P= 0.91).  These data indicate the presence of 
functional SK channels in human atrial myocytes under our experimental conditions, as 
reported in mouse [20]. 
 
Inhibition of SK channel current reduces the charge movement underlying the human 
atrial action potential 
An unusual pharmacology has been reported for the mouse action potential, with the 
duration being prolonged by UCL1684 but not by apamin [20].  It is important to determine 
whether this unusual pharmacology is present in human atria.  We elected to use action 
potential clamp of the whole-cell configuration to isolate the ionic currents underlying the 
human atrial myocyte action potential.  The effect of drug was determined by integration of 
the waveform to provide an estimate of total charge that was passed during the action 
potential voltage waveform.  Application of UCL1684 (100 nM) decreased the charge 
transfer by 20.6 ± 5.3 % (n=3) (P<0.01).  In contrast, application of apamin (100 nM) had 
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very little effect on charge transfer, with it decreasing by 5.6 ± 0.2 % (n=3) (P=0.97).  The 
effect of UCL1684 was significantly different from any effect of apamin (P=0.05).  The effect 
of these two SK current inhibitors can be seen when the drug-sensitive trace is produced 
and compared, as shown in Figure 2.  The UCL1684-sensitive trace shows a waveform that 
suggests activation of SK channels early in the action potential waveform, while the current 
inhibited by apamin is essentially flat.  These data are similar to those reported for mouse 
atria, where apamin was without a significant effect on the action potential duration but 
UCL1684 prolonged the waveform [20].  It was proposed that a heteromeric channel 
comprising SK2 and SK3 subunits exhibited this unusual pharmacology [20]. 
 
Immuno-visualization of SK2 and SK3 subunits in human atrial myocytes 
The presence of SK channel protein in human atria has been reported, with some evidence 
that expression is highest in atrial myocytes [23-25].  Our pharmacological data would 
suggest that a heteromer between SK2 and SK3 subunits might comprise the SK channel 
that contributes to action potential repolarization [20].  Human atrial myocytes were fixed, 
permeabilised and incubated with primary antibodies directed against SK2 and 3 subunits.  
Immuno-visualization showed SK2 and SK3 were expressed in acutely isolated human atrial 
myocytes, with labelling concentrated at cell periphery (Figure 3A).  The intensity of labelling 
was similar for both SK2 and SK3 subunits, suggesting that both subunits were expressed at 
approximately the same level uniformly across human atrial myocytes (Figure 3B).  
Examination of colocalization showed that 93% of SK3 subunits were overlapped with SK2 
subunits, and 94% of SK2 subunits were overlapped with SK3 subunits (Figure 3C).  These 
data suggest that both SK2 and SK3 subunits are expressed in human atrial myocytes, with 
most subunits colocalised to suggest that heteromeric channels are formed.  Expressed 
heteromeric SK2-SK3 channel current is inhibited by UCL1684, but insensitive to inhibition 
by apamin [20]. These data are consistent with the pharmacology of the current underlying 
repolarization of the atrial action potential, where only UCL1684 affected the current evoked 
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in action potential clamp (Figure 2).  Together, it is proposed that activation of heteromeric 




Expression of SK1-3 subunits has been demonstrated in a number of species, including 
human, horse, pig, rat and mouse [10, 16-18, 20].  Activation of SK channels has been 
demonstrated to contribute to action potential repolarization in human and mouse atrial 
myocytes [20, 26].  It is unusual however, that apamin is much less effective than small 
organic molecule inhibitors [20, 26].  This unusual pharmacology is apparent in reports 
suggesting that inhibition of SK channel function terminates induced atrial fibrillation (AF) in 
vivo in horse [27], rat [19], and pig [17], and in vitro in guinea pig [28] and rat [29].  
Termination of AF has been demonstrated with small organic molecules such as NS8593 
and UCL1684, but apamin was significantly less effective when tested [19, 30].  Apamin acts 
as a negative allosteric modulator, binding to both the outer pore turret and the S3-S4 
extracellular loop to inhibit channel activity [19, 27].  In contrast, small organic molecule 
inhibitors such as UCL1684 only bind the outer pore turret, with it being proposed that the 
lack of binding to the extracellular loop prevents these molecules from selecting between SK 
channel subtypes [19].  UCL1684 has been found to be very selective for SK channels, not 
affecting a number of ion channel currents that underlie the atrial action potential [20].  SK 
channel subunits of different identities can co-assemble to form functional heteromeric 
channels that display atypical pharmacology [11, 20].  For example, expressed heteromeric 
SK2-SK3 channel current was insensitive to apamin but inhibited by UCL1684 [20], which 
matched data showing that the mouse atrial action potential duration was prolonged by 
UCL1684, but not by apamin [20].  We observed a similar pharmacology with acutely 
dissociated human atrial myocytes (Figure 2).  However, in both mouse [20] and human 
(this study) apamin reduced outward current under voltage clamp (Figure 1).  The 
concentration-inhibition relationship for apamin in mouse atrial myocytes indicated a 
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sensitivity reflecting inhibition of homomeric SK2 channels [20].  These data suggest that 
both human and mouse atrial myocytes express two populations of SK channels, homomeric 
SK2 and heteromeric SK2-SK3 channels [20]. 
 
It has been proposed that inhibition of SK channel current is a therapeutic approach for the 
treatment of AF [12].  Our study suggests that only activation of SK2-SK3 heteromeric 
channels contributes to action potential repolarization in human (Figure 2) and mouse atrial 
myocytes [20]. The function of the discreet population of homomeric SK2 channels [20] is 
unknown.  It is therefore possible that there is a limited distribution of heteromeric SK2-SK3 
channels in the periphery, as expression of SK3 protein is limited to heart [12] and skeletal 
muscle [31, 32] and SK2 is not expressed in skeletal muscle [32].  This raises the possibility 
that targeting a SK2-SK3 heteromer would give a selective therapeutic effect in halting AF in 
otherwise healthy subjects [20] with less side effects.  Importantly, it is clear that like mouse 
atria, human atrial myocytes utilise a SK channel with unique pharmacology to repolarise the 
action potential that allows mouse to be a suitable translational model for future studies 
aiming at developing more effective pharmacological approaches to AF.  
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 Total (N=18) 
Age in years, median (IQR) 70 (64.3, 72.5) 
Male gender, n (%) 15/18 (83.3) 
History of atrial fibrillation at consent, n (%) 5/18 (27.8) 








Smoking history, n (%) 
Current smoker 








Medical history, n (%) 
Hypertension requiring treatment  
Myocardial infarction  
Hypercholesterolaemia 
























Pre-operative haemoglobin (g/l), median (IQR) 142 (140.3, 152.0) 










Pre-operative LV function, n (%) 
Good (EF >60%) 
Mildly impaired (EF 50-60%) 





IQR: interquartile range; NYHA: New York heart association; ECG: electrocardiogram; LV: left 
ventricular.       
$
 More than one result could be selected per patient. ^ Sinus bradycardia (n=1); sinus bradycardia 
with premature atrial complexes (n=1).  
Table 1: Baseline demographics and clinical details of consented participants whose 
samples are included in analyses 








Figure 1  Inhibition of SK channel current in whole-cell voltage-clamped human atrial 
myocytes.  Ai.  Membrane current evoked by a step depolarization to 10 mV from a holding 
potential of -80 mV.  Application of apamin (100 nM) (grey trace) reduced the amplitude of 
evoked control current (black trace), with the initial fast inward sodium current partially 
curtailed.  Aii. Normalised current-voltage relationship of current evoked by step 
depolarization from a holding potential of -80 mV ().  Application of apamin (100 nM) 
significantly reduced the amplitude of evoked current at potentials positive to -10 mV () 
(P<0.05 at -20 mV, P˂0.0001 at -10 to +10 mV).  Inset shows the current-voltage 
relationship of apamin-sensitive current, with apamn inhibiting current positive to -50 mV.  
Bi.  Outward current evoked by a step depolarization to 10 mV from a holding potential of -
80 mV (black trace) was reduced by UCL1684 (100 nM) (grey trace).  Bii.  Current-voltage 
relationship for current evoked by step depolarization from a holding potential of -80 mV in 
the absence () and presence of UCL1684 (100 nM) ().  The SK current inhibitor 
significantly inhibited current positive to -30 mV (P<0.05 at -30 mV, P<0.01 at -20 mV, 
P˂0.0001 at -10 to +10 mV).  Inset shows the current-voltage relationship for the current 
inhibited by UCL1684 (100 nM). 
 
Figure 2.  Atypical pharmacology of SK channel current underlying the atrial action 
potential.  A.  Action potential voltage command waveform delivered to voltage clamped 
human atrial myocytes.  This was generated by the Courtemanche et al human atrial AP 
model (Am J Physiol, 1998, 275, H301-H321).  B: Difference current between control and 
apamin containing solutions from a human atrial myocyte voltage clamped -80 mV, to which 
the AP command was applied. The trace profile shows little effect of apamin (100 nM).  C:  
UCL1684 (100 nM)-sensitive action potential currents evoked by subtraction of residual 
(UCL1684-insensitive) current from control current (different cell from B).  There was a clear 
outward UCL 1684-sensitive current during the applied AP command.  The waveform 
demonstrates that activation of a UCL1684-sensitive current occurs early in the action 




Figure 3.  Presence of SK2 and SK3 channel subunits in human atrial myocytes.  A.  
Confocal images (0.5-μm section) of a fixed and permeabilized cell labelled with anti-SK2 
(green) and anti-SK3 (red).  Labelling was observed at the cell periphery and 
superimposition of both images showed a significant degree of colocalization (yellow).  B.  
Graph illustrates that an apparent similar level of labelling of SK2 and SK3 subunits in 
acutely isolated human atrial myocytes.  C.  Confocal images of SK2 (green) and SK3 (red) 
showing labelling at the cell edge.  Superimposition of SK2 and SK3 channel subunit 
labelling demonstrates significant colocalization (yellow), which was quantified by using 
Mander’s coefficient.  Measured SK2 and SK3 labelling gave a Mander’s coefficient of co-
localization of SK3 overlapping SK2 by 0.94 ± 0.05 and SK2 overlapping SK3 by 093 ± 0.03. 
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